Forte Biosciences, Inc. — Director's Dealing 2017

Apr 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2017-04-19

Reporting Person: Duvall Martin J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-19	Common Stock	J	3571	$10.00	Acquired	3571	Direct

Footnotes

F1: Represents the conversion of outstanding convertible promissory notes in the aggregate principal amount of $35,000, plus an aggregate of $714.39 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $10.00 per share.